NASDAQ · KYNB
Kyntra Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KYNB: Nov 9, 2026
Kyntra Bio, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-3.66. The reported EPS for the same quarter last year was $-1.61.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-3.66 | $-2.92 | $-4.31 | 3 |
| Dec 2026 | $-3.91 | $-2.89 | $-4.80 | 3 |
| Mar 2027 | $-2.87 | $-2.87 | $-2.87 | 1 |
| Jun 2027 | $-3.08 | $-3.08 | $-3.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · The Motley Fool · Zacks · RTTNews- Fintel · Sep 17, 5:27 PM EDTLake Street Initiates Coverage of Kyntra Bio with BuyFintel reports that on September 17, 2026, Lake Street initiated coverage of Kyntra Bio (NASDAQGS:KYNB) with a Buy recommendation. According to a Form 8-K filed on August 31, 2026, the company's common stock, with a $0.01 par value, is registered under the trading symbol KYNB on
- The Motley Fool · Aug 20, 5:43 PM EDTKyntra Bio (KYNB) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 13, 5:35 PM EDTKyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue EstimatesKyntra Bio (KYNB) delivered earnings and revenue surprises of -47.17% and -173.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 12, 8:25 AM EDTKamada (KMDA) Q2 Earnings and Revenues Surpass EstimatesKamada (KMDA) delivered earnings and revenue surprises of +33.33% and +6.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 3, 10:00 AM EDTKyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Jul 30, 9:35 AM EDTVericel Corporation (VCEL) Beats Q2 Earnings and Revenue EstimatesVericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 23, 8:15 AM EDTNovoCure (NVCR) Reports Q2 Loss, Beats Revenue EstimatesNovoCure (NVCR) delivered earnings and revenue surprises of +56.67% and +5.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 12, 11:01 AM EDTKyntra Reports Phase 3 MATTERHORN Data For Roxadustat In LR-MDS; U.S. Phase 3 Planned In H2 2026(RTTNews) – Kyntra Bio (KYNB), a biopharmaceutical company, on Thursday released new data from the Phase 3 MATTERHORN trial for Roxadustat in treating anemia associated with lower-risk myelodysplastic syndrome.
- The Motley Fool · May 11, 6:10 PM EDTKyntra Bio (KYNB) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 11, 6:05 PM EDTKyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue EstimatesKyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 8:50 AM EDTBeam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue EstimatesBeam Therapeutics (BEAM) delivered earnings and revenue surprises of -4.60% and +52.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 14, 12:00 PM EDTKyntra Bio (KYNB) Upgraded to Buy: Here's What You Should KnowKyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Kyntra Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.